Recruiting × OTHER × Waldenstrom Macroglobulinemia × Clear all ZEBRA
Phase 2 Recruiting
55 enrolled
Epcoritamab in Previously Treated WM
Phase 2 Recruiting
20 enrolled
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Recruiting
100 enrolled
PRAME
Recruiting
1,000 enrolled
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Recruiting
10,000 enrolled
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Phase 2 Recruiting
30 enrolled
VIWA-1
Phase 2 Recruiting
80 enrolled
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Phase 2 Recruiting
40 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 Recruiting
46 enrolled
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
Phase NA Recruiting
50 enrolled
SLP-rares
Phase NA Recruiting
90 enrolled
This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process
Recruiting
90 enrolled
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 Recruiting
148 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Phase NA Recruiting
40 enrolled
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Recruiting
200 enrolled
SLPRaresHvisc
Phase NA Recruiting
100 enrolled
Loncastuximab Tesirine in WM
Phase 2 Recruiting
36 enrolled
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Phase 2 Recruiting
42 enrolled
ZBR
Phase 2 Recruiting
42 enrolled
RAINBOW
Phase 2/3 Recruiting
148 enrolled
Ballondor
Phase 2 Recruiting
54 enrolled